Satiro Nakamura De Oliveira

Satiro Nakamura De Oliveira

Auto-generated profile, based on publicly available information

Satiro Nakamura De Oliveira

Dept. of Pediatrics, UCLA, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2017 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
FEFlorian Eichler
Florian Eichler
CDChristine Duncan
Christine Duncan
PMPatricia L. Musolino
Patricia L. Musolino
POPaul J. Orchard
Paul J. Orchard
SOSatiro De Oliveira
Satiro De Oliveira
DWDavid A. Williams
David A. Williams
In X-linked adrenoleukodystrophy, mutations in ABCD1 lead to loss of function of the ALD protein. Cerebral adrenoleukodystrophy is characterized by demyelination and neurodegeneration. Disease progression, which leads to loss of neurologic function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation. We enrolled boys with cerebral adrenoleukodystrophy in a single-group, open-label, phase 2–3 safety and efficacy study. Patients were required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MRI) at screening. The investigational therapy involved infusion of autologous CD34+ cells transduced with the elivaldogene tavalentivec (Lenti-D) lentiviral vector. In this interim analysis, patients were assessed for the occurrence of graft-versus-host disease, death, and major functional disabilities, as well as changes in neurologic function and in the extent of lesions on MRI. The primary end point was being alive and having no major functional disability at 24 months after infusion. A total of 17 boys received Lenti-D gene therapy. At the time of the interim analysis, the median follow-up was 29.4 months (range, 21.6 to 42.0). All the patients had gene-marked cells after engraftment, with no evidence of preferential integration near known oncogenes or clonal outgrowth. Measurable ALD protein was observed in all the patients. No treatment-related death or graft-versus-host disease had been reported; 15 of the 17 patients (88%) were alive and free of major functional disability, with minimal clinical symptoms. One patient, who had had rapid neurologic deterioration, had died from disease progression. Another patient, who had had evidence of disease progression on MRI, had withdrawn from the study to undergo allogeneic stem-cell transplantation and later died from transplantation-related complications. Early results of this study suggest that Lenti-D gene therapy may be a safe and effective alternative to allogeneic stem-cell transplantation in boys with early-stage cerebral adrenoleukodystrophy. Additional follow-up is needed to fully assess the duration of response and long-term safety. (Funded by Bluebird Bio and others; STARBEAM ClinicalTrials.gov number, NCT01896102; ClinicalTrialsRegister.eu number, 2011-001953-10.)

9 October 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SHSalima Hacein-Bey-Abina
Salima Hacein-Bey-Abina
SPSung-Yun Pai
Sung-Yun Pai
HGH. Bobby Gaspar
H. Bobby Gaspar
MAMyriam Armant
Myriam Armant
CBCharles C. Berry
Charles C. Berry
ATAdrian J. Thrasher
Adrian J. Thrasher
In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus–based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1. We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc). All patients received bone marrow–derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients. This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.)

1 May 2018 in Cell Reports
Verified
Journal Article
Open access
CKCaroline Y. Kuo
Caroline Y. Kuo
JLJoseph D. Long
Joseph D. Long
BCBeatriz Campo-Fernandez
Beatriz Campo-Fernandez
SOSatiro de Oliveira
Satiro de Oliveira
ACAaron R. Cooper
Aaron R. Cooper
DKDonald B. Kohn
Donald B. Kohn
X-linked hyper-immunoglobulin M (hyper-IgM) syndrome (XHIM) is a primary immunodeficiency due to mutations in CD40 ligand that affect immunoglobulin class-switch recombination and somatic hypermutation. The disease is amenable to gene therapy using retroviral vectors, but dysregulated gene expression results in abnormal lymphoproliferation in mouse models, highlighting the need for alternative strategies. Here, we demonstrate the ability of both the transcription activator-like effector nuclease (TALEN) and clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9) platforms to efficiently drive integration of a normal copy of the CD40L cDNA delivered by Adeno-Associated Virus. Site-specific insertion of the donor sequence downstream of the endogenous CD40L promoter maintained physiologic expression of CD40L while overriding all reported downstream mutations. High levels of gene modification were achieved in primary human hematopoietic stem cells (HSCs), as well as in cell lines and XHIM-patient-derived T cells. Notably, gene-corrected HSCs engrafted in immunodeficient mice at clinically relevant frequencies. These studies provide the foundation for a permanent curative therapy in XHIM.

19 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JBJason N. Belling
Jason N. Belling
LHLiv K. Heidenreich
Liv K. Heidenreich
Zhenhua TianZhenhua Tian
Zhenhua Tian
AMAlexandra M. Mendoza
Alexandra M. Mendoza
TCTzu-Ting Chiou
Tzu-Ting Chiou
SJSteven J. Jonas
Steven J. Jonas
Significance: Commercial strategies to deliver biomolecular cargo ex vivo (e.g., electroporation, lipofection) to clinically relevant cell lines are limited by toxicity, cost, and throughput. These technical limitations have inhibited development of these technologies into streamlined clinical platforms for manufacturing gene-modified stem cells and cancer immunotherapies. Here, we demonstrate an acoustofluidic platform capable of delivering plasmids with high throughput to human T lymphocytes, peripheral blood mononuclear cells, and CD34 + hematopoietic stem and progenitor cells. Acoustofluidic-treated cells showed evidence of cytosolic DNA delivery, endocytic DNA aggregation, and nuclear membrane rupture. Collectively, these observations demonstrate the utility of this method as a research tool for gene editing applications and mechanistic studies of plasma membrane and nuclear membrane repair.

1 October 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
YZYanni Zhu
Yanni Zhu
DSDrake J. Smith
Drake J. Smith
YZYang Zhou
Yang Zhou
YLYan-Ruide Li
Yan-Ruide Li
JYJiaji Yu
Jiaji Yu
LYLili Yang
Lili Yang

10 October 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
FEFlorian Sebald Eichler
Florian Sebald Eichler
CDChristine N. Duncan
Christine N. Duncan
PMPatricia L. Musolino
Patricia L. Musolino
TLTroy Lund
Troy Lund
AGAshish Gupta
Ashish Gupta
DWDavid A. Williams
David A. Williams
Cerebral adrenoleukodystrophy is a severe form of X-linked adrenoleukodystrophy characterized by white-matter disease, loss of neurologic function, and early death. Elivaldogene autotemcel (eli-cel) gene therapy, which consists of autologous CD34+ cells transduced with Lenti-D lentiviral vector containing ABCD1 complementary DNA, is being tested in persons with cerebral adrenoleukodystrophy. In a phase 2-3 study, we evaluated the efficacy and safety of eli-cel therapy in boys with early-stage cerebral adrenoleukodystrophy and evidence of active inflammation on magnetic resonance imaging (MRI). The primary efficacy end point was survival without any of six major functional disabilities at month 24. The secondary end points included overall survival at month 24 and the change from baseline to month 24 in the total neurologic function score. A total of 32 patients received eli-cel; 29 patients (91%) completed the 24-month study and are being monitored in the long-term follow-up study. At month 24, none of these 29 patients had major functional disabilities; overall survival was 94%. At the most recent assessment (median follow-up, 6 years), the neurologic function score was stable as compared with the baseline score in 30 of 32 patients (94%); 26 patients (81%) had no major functional disabilities. Four patients had adverse events that were directly related to eli-cel. Myelodysplastic syndrome (MDS) with excess blasts developed in 1 patient at month 92; the patient underwent allogeneic hematopoietic stem-cell transplantation and did not have MDS at the most recent follow-up. At a median follow-up of 6 years after lentiviral gene therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities had no major functional disabilities. However, insertional oncogenesis is an ongoing risk associated with the integration of viral vectors. (Funded by Bluebird Bio; ALD-102 and LTF-304 ClinicalTrials.gov numbers NCT01896102 and NCT02698579, respectively.).